The multifaceted and controversial immunometabolic actions of adiponectin

Trends in Endocrinology and Metabolism

Volumn 25, Issue 9, 2014, Pages 444-451

  Esmaili, Saeed ^a,b   Xu, Amin ^c,d   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adiponectin; Glucose homeostasis; Immunometabolism; Insulin sensitivity

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CADHERIN; GLUCOSE; INSULIN; RECOMBINANT ADIPONECTIN; RECOMBINANT PROTEIN; STREPTOZOCIN; T CADHERIN; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CELL DIFFERENTIATION; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN SENSITIVITY; KUPFFER CELL; MACROPHAGE; METABOLIC DISORDER; METABOLIC REGULATION; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; AGONISTS; ANIMAL; BIOLOGICAL MODEL; ENERGY METABOLISM; HOMEOSTASIS; INSULIN RESISTANCE; MUSCLE CELL; SIGNAL TRANSDUCTION; SYNOVIUM;

ADIPONECTIN; ANIMALS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; INSULIN RESISTANCE; KUPFFER CELLS; MACROPHAGES; MODELS, BIOLOGICAL; MUSCLE CELLS; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 84906794224     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.06.001     Document Type: Review

References (71)

1. Fantuzzi G. Adiponectin in inflammatory and immune-mediated diseases. Cytokine 2013, 64:1-10.
2. Gomez R., et al. What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat. Rev. Rheumatol. 2011, 7:528-536.
3. Chen X., et al. Adiponectin: a biomarker for rheumatoid arthritis?. Cytokine Growth Factor Rev. 2013, 24:83-89.
4. Scherer P.E., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995, 270:26746-26749.
5. Comuzzie A.G., et al. The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome. J. Clin. Endocrinol. Metab. 2001, 86:4321-43215.
6. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006, 6:772-783.
7. Hu E., et al. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996, 271:10697-10703.
8. Arita Y., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
9. Yamauchi T., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7:941-946.
10. Xu A., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003, 112:91-100.
11. Kadowaki T., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006, 116:1784-1792.
12. Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
13. Yamauchi T., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 2007, 13:332-339.
14. Hug C., et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10308-10313.
15. Adachi Y., et al. An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways. Virchows Arch. 2006, 448:311-318.
16. Awazawa M., et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011, 13:401-412.
17. Berg A.H., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001, 7:947-953.
18. Combs T.P., et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 2001, 108:1875-1881.
19. Mao X., et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 2006, 8:516-523.
20. Mitsuuchi Y., et al. Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene 1999, 18:4891-4898.
21. Miller R.A., et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J. Clin. Invest. 2011, 121:2518-2528.
22. Haluzik M.M., Haluzik M. PPAR-alpha and insulin sensitivity. Physiol. Res. 2006, 55:115-122.
23. Lin H.V., et al. Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes 2007, 56:1969-1976.
24. Lancaster G.I., Febbraio M.A. Adiponectin sphings into action. Nat. Med. 2011, 17:37-38.
25. Holland W.L., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 2011, 17:55-63.
26. Ouchi N., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
27. Maeda N., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8:731-737.
28. Ohashi K., et al. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol. Metab. 2014, 10.1016/j.tem.2014.03.009.
29. Yamaguchi N., et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 2005, 579:6821-6826.
30. Kumada M., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109:2046-2049.
31. Ohashi K., et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J. Biol. Chem. 2010, 285:6153-6160.
32. Takemura Y., et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest. 2007, 117:375-386.
33. Haugen F., Drevon C.A. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 2007, 148:5478-5486.
34. Tsao T.S., et al. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30kDa (Acrp30). J. Biol. Chem. 2002, 277:29359-29362.
35. + T cells. J. Biol. Chem. 2012, 287:36896-36904.
36. Foster S.L., et al. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
37. Monticelli S., Natoli G. Short-term memory of danger signals and environmental stimuli in immune cells. Nat. Immunol. 2013, 14:777-784.
38. Park P.H., et al. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J. Biol. Chem. 2007, 282:21695-21703.
39. Fairfax B.P., et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science 2014, 10.1126/science.1246949.
40. Dimas A.S., et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 2009, 325:1246-1250.
41. Fairfax B.P., et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat. Genet. 2012, 44:502-510.
42. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
43. Odegaard J.I., Chawla A. The immune system as a sensor of the metabolic state. Immunity 2013, 38:644-654.
44. Pearce E.L., Pearce E.J. Metabolic pathways in immune cell activation and quiescence. Immunity 2013, 38:633-643.
45. Chang C.H., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013, 153:1239-1251.
46. Haschemi A., et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab. 2012, 15:813-826.
47. Blagih J., Jones R.G. Polarizing macrophages through reprogramming of glucose metabolism. Cell Metab. 2012, 15:793-795.
48. Mandal P., et al. Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J. Biol. Chem. 2011, 286:13460-13469.
49. Stanya K.J., et al. 07 Direct control of hepatic glucose production by interleukin-13 in mice. J. Clin. Invest. 2013, 123:261-271.
50. Odegaard J.I., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008, 7:496-507.
51. Satoh T., et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature 2013, 495:524-528.
52. Kim J.Y., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 2007, 117:2621-2637.
53. Liu Q., et al. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14568-14573.
54. Luo N., et al. Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages. Atherosclerosis 2013, 228:124-135.
55. Nakatsuji H., et al. Accumulation of adiponectin in inflamed adipose tissues of obese mice. Metabolism 2014, 63:542-553.
56. Xu X., et al. Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab. 2013, 18:816-830.
57. 2+ and AMPK/SIRT1. Nature 2010, 464:1313-1319.
58. Okada-Iwabu M., et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013, 503:493-499.
59. Rhee J., et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4012-4017.
60. Handa P., et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 2014, 10.1002/hep.26946.
61. Burgess S.C., et al. Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha)-deficient mice. J. Biol. Chem. 2006, 281:19000-19008.
62. Foretz M., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120:2355-2369.
63. Tang C.H., et al. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J. Immunol. 2007, 179:5483-5492.
64. Thakur V., et al. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G998-G1007.
65. Mandal P., et al. The anti-inflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010, 51:1420-1429.
66. Lindberg S., et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am. J. Cardiol. 2013, 111:1139-1145.
67. Kizer J.R., et al. Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation 2012, 126:2951-2961.
68. Rho Y.H., et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum. 2009, 60:1906-1914.
69. Honsawek S., et al. Serum adiponectin and transient elastography as non-invasive markers for postoperative biliary atresia. BMC Gastroenterol. 2011, 11:16.
70. Kaser S., et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J. Intern. Med. 2005, 258:274-280.
71. Chan K.H., et al. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int. J. Tuberc. Lung Dis. 2010, 14:1193-1200.